Scholarlink

<p>Photodynamic Therapy (PDT) employs light and non-toxic components, including a photosensitizer (PS) and oxygen, to induce cellular effects and target cancer cells. Bacteriochlorin (Bch), a PS absorbing longer wavelengths, offers deeper tissue penetration, broadening PDT’s therapeutic reach. A liposomal formulation (LF) was developed to improve solubility, stability, bioavailability, and enable controlled, targeted drug release to enhance Bch’s effectiveness. The present study aims to describe a new third generation of low-cost Bch, reducing the required dose for cancer cell death. Researchers compared the photodynamic activity of Bch in its free form and as an LF, evaluating its efficiency and therapeutic potential in vitro. Bch was obtained from bacterial precursors via extraction and transesterification. LF was produced using the film hydration method, a low-cost method without the need for expensive equipment. Absorbance and cell viability (MTT assay) data were analyzed statistically (ANOVA and Tukey test, 95% confidence interval). Results showed LF significantly outperformed free Bch in all tested cell lines. LF exhibited 140 times higher potency in MIA PaCa-2 cells (IC<sub>50</sub> = 6 nM) and 22 times higher potency in MRC-5 cells (IC<sub>50</sub> = 3 nM) compared to free Bch. Furthermore, the presence of LF led to the protection of Bch from photodegradation, thereby enhancing its performance. In conclusion, PDT using liposomal Bch demonstrated superior efficiency, low systemic toxicity, and no drug resistance, reinforcing its clinical potential.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Liposome-encapsulated bacteriochlorin: tumor cell inactivation using photodynamic therapy

  • 期刊论文

  • 发表日期：

    2025年5月13日

查看全文
  • Priscila Romero Mazzini Pereira,
  • Juliana Kafka Bilha,
  • Clovis Wesley Oliveira de Souza,
  • Nayara Rezende,
  • Antônio Claudio Tedesco,
  • Jorge Luiz María Ruiz,
  • Marciana Pierina Uliana

摘要

Photodynamic Therapy (PDT) employs light and non-toxic components, including a photosensitizer (PS) and oxygen, to induce cellular effects and target cancer cells. Bacteriochlorin (Bch), a PS absorbing longer wavelengths, offers deeper tissue penetration, broadening PDT’s therapeutic reach. A liposomal formulation (LF) was developed to improve solubility, stability, bioavailability, and enable controlled, targeted drug release to enhance Bch’s effectiveness. The present study aims to describe a new third generation of low-cost Bch, reducing the required dose for cancer cell death. Researchers compared the photodynamic activity of Bch in its free form and as an LF, evaluating its efficiency and therapeutic potential in vitro. Bch was obtained from bacterial precursors via extraction and transesterification. LF was produced using the film hydration method, a low-cost method without the need for expensive equipment. Absorbance and cell viability (MTT assay) data were analyzed statistically (ANOVA and Tukey test, 95% confidence interval). Results showed LF significantly outperformed free Bch in all tested cell lines. LF exhibited 140 times higher potency in MIA PaCa-2 cells (IC50 = 6 nM) and 22 times higher potency in MRC-5 cells (IC50 = 3 nM) compared to free Bch. Furthermore, the presence of LF led to the protection of Bch from photodegradation, thereby enhancing its performance. In conclusion, PDT using liposomal Bch demonstrated superior efficiency, low systemic toxicity, and no drug resistance, reinforcing its clinical potential.

Graphical Abstract